PT3055333T - Uso de um inibidor de pcsk9 para tratar a hiperlipidemia - Google Patents

Uso de um inibidor de pcsk9 para tratar a hiperlipidemia

Info

Publication number
PT3055333T
PT3055333T PT148025273T PT14802527T PT3055333T PT 3055333 T PT3055333 T PT 3055333T PT 148025273 T PT148025273 T PT 148025273T PT 14802527 T PT14802527 T PT 14802527T PT 3055333 T PT3055333 T PT 3055333T
Authority
PT
Portugal
Prior art keywords
pcsk9 inhibitor
treat hyperlipidemia
hyperlipidemia
treat
pcsk9
Prior art date
Application number
PT148025273T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of PT3055333T publication Critical patent/PT3055333T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PT148025273T 2013-10-11 2014-10-10 Uso de um inibidor de pcsk9 para tratar a hiperlipidemia PT3055333T (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361890154P 2013-10-11 2013-10-11
US201461923103P 2014-01-02 2014-01-02
US201461955514P 2014-03-19 2014-03-19
US201462004620P 2014-05-29 2014-05-29
US201462025104P 2014-07-16 2014-07-16
EP14306221 2014-07-31
US201462054571P 2014-09-24 2014-09-24
EP14306584 2014-10-09

Publications (1)

Publication Number Publication Date
PT3055333T true PT3055333T (pt) 2020-03-11

Family

ID=68918439

Family Applications (1)

Application Number Title Priority Date Filing Date
PT148025273T PT3055333T (pt) 2013-10-11 2014-10-10 Uso de um inibidor de pcsk9 para tratar a hiperlipidemia

Country Status (4)

Country Link
ES (1) ES2779126T3 (zh)
IL (1) IL271456B (zh)
PT (1) PT3055333T (zh)
TW (1) TWI723478B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114525258A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达pcsk9阻断物的多能干细胞或其衍生物及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
PE20140372A1 (es) * 2011-01-28 2014-03-24 Sanofi Sa Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول

Also Published As

Publication number Publication date
ES2779126T3 (es) 2020-08-13
IL271456B (en) 2021-08-31
IL271456A (en) 2020-01-30
TWI723478B (zh) 2021-04-01
TW202021615A (zh) 2020-06-16

Similar Documents

Publication Publication Date Title
IL244995A0 (en) Using pcsk9 inhibitor to treat hyperlipidemia
IL279682A (en) Benzoquinolone compounds as VMAT2 inhibitors
PT3080100T (pt) Inibidores de desmetilase-1 específica de lisina
EP2948450A4 (en) METALLOENZYMINHIBITORVERBINDUNGEN
HK1223926A1 (zh) 用於製備 抑制劑的方法
ZA201702252B (en) A selective inhibitor of prosphatidylinositol 3-kinase-gamma
EP2958964A4 (en) TREATMENT OF FREQUENTLY AFFECTED SURFACES TO IMPROVE HYGIENE
EP2962186A4 (en) PROVISION OF CODE CHANGE JOB PACKAGES OF VARIOUS SIZE FOR VALIDATORS
EP3632467C0 (en) INHIBITORS OF COMPLEMENT FACTOR H
HK1222339A1 (zh) 金屬-β-內酰胺酶的抑制劑
ZA201409181B (en) Treatment of waste water
HK1221645A1 (zh) 的苯並喹啉抑制劑
ZA202207530B (en) Use of phenoxypropylamine compounds to treat depression
IL240763B (en) The halopyrazoles as thrombin inhibitors
DK2928477T3 (da) Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
PT3055333T (pt) Uso de um inibidor de pcsk9 para tratar a hiperlipidemia
PT3689913T (pt) Uso de um inibidor de pcsk9 para tratar a hiperlipidemia
ZA201409002B (en) Treatment of waste water
GB201308117D0 (en) Inhibitor of calcifying disorders
GB201322036D0 (en) New therapeutic uses of enzyme inhibitors
GB201310488D0 (en) New therapeutic uses of enzyme inhibitors